“On the heels of a series of lawsuits led by Bristol Myers Squibb (BMS), PhRMA, and their industry peers to block implementation of the Inflation Reduction Act’s Medicare Drug Price Negotiation Program, BMS reported $1.9 billion in Q3 earnings today. …” President Biden’s Inflation Reduction Act calls for annual negotiations on prices for ten drugs at a time that Medicare pays for, and also reduces the price of insulin to $35.